

This article was downloaded by:

On: 29 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Supramolecular Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713649759>

Molecular Structure and Affinity to 5-HT_{1A} Receptor of Chlorophenyl(Piperazinylalkyl)Phthalimides

Yu. M. Chumakov^a; Yu. A. Simonov^a; S. G. Soboleva^b; V. M. Sava^b; S. A. Andronati^b; M. Gdaniec^c; G. Bocelli^d

^a Academy of Sciences of Moldova, Institute of Applied Physics, Kishinev, Moldova ^b Academy of Sciences of Ukraine, A. V. Bogatsky Physico-Chemical Institute, Odessa, Ukraine ^c Faculty of Chemistry, A. Mickiewicz University, Poznań, Poland ^d CSSD-CNR, Parma, Italy

To cite this Article Chumakov, Yu. M. , Simonov, Yu. A. , Soboleva, S. G. , Sava, V. M. , Andronati, S. A. , Gdaniec, M. and Bocelli, G.(2008) 'Molecular Structure and Affinity to 5-HT_{1A} Receptor of Chlorophenyl(Piperazinylalkyl)Phthalimides', *Supramolecular Chemistry*, 12: 2, 225 – 227

To link to this Article: DOI: 10.1080/10610270008027456

URL: <http://dx.doi.org/10.1080/10610270008027456>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Molecular Structure and Affinity to 5-HT_{1A} Receptor of Chlorophenyl(Piperazinylalkyl)Phthalimides

YU.M. CHUMAKOV^a, YU.A. SIMONOV^a, S.G. SOBOLEVA^b, V.M. SAVA^b, S.A. ANDRONATI^b, M. GDANIEC^c and G. BOCELLI^d

^aInstitute of Applied Physics, Academy of Sciences of Moldova, 2028 Kishinev, Moldova, ^bA.V. Bogatsky Physico-Chemical Institute, Academy of Sciences of Ukraine, Odessa, Ukraine, ^cFaculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland and ^dCSSD-CNR, 43100 Parma, Italy

(In final form March 31, 2000)

X-ray crystallography, quantum-chemical calculations and conformational analysis have been employed to study chlorophenyl(piperazinylalkyl)phthalimides, potential ligands of 5-HT_{1A} receptor. The molecular recognition of investigated compounds by 5-HT_{1A} serotonin receptor has been estimated according to their ability to inhibit the [³H8]-DPAT binding. The model for 5-HT_{1A} pharmacophore has been proposed based on crystal structures of N-(aryl)piperazinyl – alkylphthalimides.

Keywords: psychotropic agents, chlorophenyl(piperazinylalkyl)phthalimides, serotonin receptors, affinity, pharmacophore

The heteroaromatic- or aryl-piperazine derivatives have been widely investigated as potential psychotropic agents. Their neuroleptic and anxiolytic properties result from the interaction with serotonin and dopamine receptors. Mechanism of biological action of these compounds has been related to ligand-receptor self-assembly. To clarify the ligand-receptor mode of interaction it is necessary to determine the electronic and conformational factors that affect recognition and binding processes. Therefore X-ray crystallography, quantum-chemical calculations and conformational analysis have been employed to study

chlorophenyl(piperazinylalkyl)phthalimides I-V, potential 5-HT_{1A} receptor ligands (Fig. 1). The molecular recognition of the compounds I-III has been estimated according to their ability to inhibit the [³H8]-DPAT binding with 5-HT_{1A} serotonin receptor. The K_i values for the compounds I-III (5.5, 6.3, 14.0 nM) indicate high affinity of these substances to this receptor.

The Hibert's two-point model [1] of pharmacophore binding to 5-HT_{1A}receptor requires an aromatic ring and a basic nitrogen atom N2 placed ca. 5.2–5.6 Å from the aromatic ring centroid. The pharmacophores for agonist and antagonist binding sites differ in the out-of-plane displacements of the basic nitrogen atom from the aromatic ring which should have the value of 0.2 Å in the agonists and ca. 1.6 Å in the antagonists.

All studied molecules I-V, for which structures have been determined by X-ray analysis, show the distance of the basic nitrogen atom to the aryl nucleus in the range 5.6–6.2 Å and the out-of-plane displacements of the nitrogen atom in the range 0.5–0.7 Å. All molecules are in the

* Author for correspondence.





FIGURE 1 Superposition of molecular conformations observed in crystals for compounds I – V

fully-extended conformation. Thus, structural and conformational requirements for agonist ligands of 5-HT_{1A} receptor are fulfilled by the molecules I-V. Conformational analysis of I-V showed that the rotation around single bonds in alkyl spacer can lead to a claw-like shape of the molecule. This brings the basic nitrogen atom close (4.2–6.5 Å) to another lipophylic part of the molecule – to the phthalimide fragment centroid. These results agree with the data reported in [2], where for the similar compounds the claw-like conformation was proposed in solution based on NMR measurements. In the fully-extended conformations observed in crystals the distances between the basic N2 atom and the phthalimide fragment are much longer (8.7–9.2 Å).

The high occupied molecular orbital which characterises the donor properties of the molecules I-V are determined mainly by the N1 atom p_π-orbital and the phenyl ring p_π-orbitals what is in line with Humbert's [3] model of aromatic ring binding site. The interaction sites can be conveniently characterised with the aid of the molecular electrostatic potential (MEP) [4]. For molecules I-V the MEP (Fig. 2) is localised in the region of carbonyl oxygen atoms of the phthalimide fragment and in the region of phenyl and piperazine rings.

Taking into account the gathered information about the structure of N-(aryl)piperazinylalkyl-phthalimides we felt that the model for 5-HT_{1A} pharmacophore requires some reconsideration which would include the following facts:





FIGURE 2 Distribution of MEP for compounds I-III

1. all important binding sites of N-(aryl)piperazinyl-alkylphthalimides have to be included in structural parameters describing the model for 5HT_{1A} pharmacophore,
2. the proposed model should be independent on the length of alkyl spacer.

The following parameters satisfy the above-mentioned requirements (Fig. 3):

$$1) \Delta_1 = |d_1 - d_2|,$$

where d₁ is the distance between the phenyl ring centroid and (N1C7C10) fragment and d₂ is the distance between the phthalimide centroid and (N1C7C10) fragment.

FIGURE 3 Scheme for 5-HT_{1A} pharmacophore model

$$2) \Delta_2 = |d_3 - d_4|,$$

where d₃ and d₄ are the distances between the centre of phenyl ring and oxygen atoms O1 and O2 respectively.

For compounds I-III, showing high affinity to the 5-HT_{1A} receptor, Δ_1 and Δ_2 values are in the range 3.86–6.42 Å and 0.16–1.90 Å, respectively. For inactive N-(aryl)piperazinyl-alkylphthalimides derivatives [5,6] the corresponding values are 0.477, 3.035 Å and 2.017, 2.018 Å, respectively. Thus we could assume that for ligands with significant affinity to 5-HT_{1A} receptors the values of Δ_1 and Δ_2 satisfy the following conditions:

$$\Delta_1 > 3.8 \text{ \AA} \text{ and } \Delta_2 < 2.0 \text{ \AA}.$$

Acknowledgements

This research has been supported by the INTAS project 94-839.

References

- [1] Hibert, M.F., Gittos, M.W., Middlemiss, D.N., Mir, A.K., Fozard J.R. (1988). *J. Med. Chem.* **31**, 1087.
- [2] Bondarev M.L., Kaliuskii A.R., Shapiro Yu. E, Andronati S.A. (1991). *Ukr. Khim. Zhurn.*, **57**, 986.
- [3] Humber L.G., Bruderlein F.T., Philipp A.H., Götz M.G., Voith K. (1979). *J. Med. Chem.* **22**, 761.
- [4] Chilmończyk Z., Leś A., Woźniakowska A., Cybulski J., Koziol A.E., Gdaniec M. (1995). *J. Med. Chem.* **38**, 1701.
- [5] Andronati S.A., Simonov Yu. A., Dvorkin A.A., Bondarev M.L., Yavorsky A.S., Chumakov Yu. M (1993). *Dokl. Akad. Nauk Ukr.*, **11**, 136.
- [6] Andronati S.A., Simonov Yu. A., Chumakov Y.M., Gdaniec M., Bondarev M.L., Polyshchuk A.A., Karasiova G.L. (1996). *Zh. Obsh. Khim.*, **10**, 1736.